Stockreport

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Cybin Inc.  (HELP) 
PDF Statistically significant (pCare (“SoC”) at 6 weeksDurable effects sustained through at least 6 monthsIn Phase 1 trial most participants were ready for discharge within [Read more]